Zoetis Inc. (NYSE:ZTS) Q4 2024 Earnings Call Transcript
Operator: Welcome to the Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast for Zoetis.
Zoetis Inc. (ZTS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Unisphere Establishment Hani Lazkani (Ceo) | 4,800,000 | $782,064,000 | 6.81% | |
| 2. | Cantillon Capital Management William Von Mueffling | 1,293,251 | $210,709,386 | +1% | 1.27% |
| 3. | Citadel Investment Group Ken Griffin | 1,090,499 | $177,675,002 | 0.03% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 788,429 | $128,458,739 | -3% | 0.15% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 676,635 | $110,244,141 | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.48 | 2,100 | Director | 7,590 | 2021-02-19 | Filing | |
| $164.89 | 2,900 | Director | 5,490 | 2021-02-19 | Filing | |
| $163.80 | 2,590 | Director | 2,590 | 2021-02-19 | Filing | |
| $74.56 | 10 | Director | 17 | 2018-01-11 | Filing | |
| $50.31 | 7 | Director | 7 | 2016-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $171.18 | 326 | Officer | 16,107 | 2025-02-11 | Filing | |
| $177.46 | 3,477 | Officer | 3,249 | 2024-11-25 | Filing | |
| $151.17 | 923 | Officer | 14,800 | 2024-04-18 | Filing | |
| $173.33 | 923 | Officer | 15,723 | 2024-03-18 | Filing | |
| $182.68 | 1,370 | Director | 9,994 | 2024-03-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 41,366,877 | $6,739,905,269 | 0.11% | |
| 2. | 38,708,206 | $6,306,728,019 | 0.12% | |
| 3. | 19,842,846 | $3,232,849,984 | 0.12% | |
| 4. | 16,011,510 | $2,608,755,324 | 2.37% | |
| 5. | 11,844,667 | $1,929,852,071 | 0.13% |
News See All
10 Best Drug Stocks to Buy Now
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for medicines in China.
Zoetis Inc. (ZTS): A Bull Case Theory
We came across a bullish thesis on Zoetis Inc. (ZTS) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.
Retirement Stock Portfolio: 10 Healthcare Stocks to Buy
Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth potential, and ability to provide steady income through dividends.
13 Best Pharma Dividend Stocks To Buy In 2024
The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower deal values, reflecting a shift toward smaller, more strategic transactions.
Zoetis Inc. (ZTS): A Bull Case Theory
We came across a bullish thesis on Zoetis Inc. (NYSE:ZTS) on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.
12 Most Profitable Pharmaceutical Stocks Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...
Wells Fargo's Best Growth Stocks: 28 Stocks With The Highest Consensus EPS Growth Estimates
With the interest rate cycle kicking off in the US, stocks that are exposed to consumer and business spending are starting to see a favorable economic outlook.
Zoetis Inc. (NYSE:ZTS) Q3 2024 Earnings Call Transcript
Operator: Welcome to the Third Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
10 Best Pet Stocks To Invest In According to Analysts
The pet industry is a rapidly growing sector.
Billionaire Hedge Funds
